TransThera Sciences (Nanjing) Inc (02617.HK)価格

TransThera Sciences (Nanjing), Inc. engages in the research and development of clinical biopharmaceutics. The company is headquartered in Nanjing, Jiangsu and currently employs 121 full-time employees. The company went IPO on 2025-06-23. The firm's core product Tinengotinib is a registrational clinical stage, internally discovered and developed, MTK inhibitor indicated for certain relapsed or refractory, drug-resistant solid tumors. The firm's oncology pipeline includes TT-00973 (against AXL), TT-01488 (for hematologic malignancies), TT-01688 (for inflammatory diseases) and TT-00920 (for chronic heart failure). The products are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC). The company is also applied to cure hepatocellular carcinoma, breast cancer, biliary tract cancer and Pan-FGFR solid tumor.